Investors in Iot

Invivo Partners, founded by Albert Ferrer and Luis Pareras, is a management company specializing in early-stage investments in the healthcare sector. They leverage a team of highly skilled professionals with expertise in scientific, technical, and financial analysis, supported by a strong network within the health ecosystem. Managed under Invivo Partners, Invivo Ventures operates based on the success of their initial fund, Healthequity, which closed at 60 million euros after registration with CNMV in 2019. Backed by prominent institutions and private investors, Invivo Partners has achieved notable exits and significant funding for their portfolio companies, emphasizing groundbreaking scientific innovations. Their strategic insights into Technology Transfer and ability to identify emerging trends position them as a leading player in Europe's Technology Transfer landscape.

Asabys Partners is a venture capital firm based in Barcelona that invests broadly in human healthcare. The firm is active in the health-tech and biopharma industries, targeting investments in Spain and internationally in highly innovative and transformative technologies. Motivated by the goal of pushing the boundaries of science and medicine, Asabys Partners sources and finances the most disruptive technologies and collaborates with top internal and external talents in the industry. With an entrepreneurial spirit, the firm seeks to be involved in the building and management of its companies, considering itself not just as investors, but as partners and collaborators to its portfolio companies.

They partner with entrepreneurs and scientists who challenge conventional thinking and tackle complex problems. Their focus is on investing in innovative solutions with the potential to disrupt market structures. They prioritize businesses that embody agility, scalability, and sustainability in their operations and growth strategies.

Axilium Holding was established in Gothenburg, Sweden in 2018. Empowered with significant investment experience in several fields, a wide professional network, and a strong desire to succeed, the two founders established an innovative investment company focusing on early stage Technology and Life Science companies based predominantly in Europe.

TEAL Impact VC is an early-stage, impact-driven investment firm focused on Europe and the UK, seeking the best combination of team, product, and impact. They support companies from early to growth stages, enhancing their business models and measuring impact. Known for being founder-friendly, lightning fast, hands-on, and collaborative, TEAL Impact VC leverages a diverse and experienced team to drive success and impactful results.

Fairpoint Capital is a B2B technology investment fund originally established by SEB Venture Capital's technology team, now operating independently with SEB as its main investor. With over two decades of experience in technology venture capital, Fairpoint Capital focuses on minority investments in early growth stage companies, spanning from late seed to B round funding. Initial investments range from 10-40 million SEK, with potential for increased exposure over the holding period. The fund primarily targets the Nordic region, particularly Sweden, but operates without formal geographic restrictions. Fairpoint Capital seeks unique technologies and business models with scalability and sustainable competitive advantages, targeting global markets with strong growth potential and proven commercial viability. Key sectors of interest include AI, IoT, Cloud, Robotics, and Additive Manufacturing, among others.

Eir Ventures, based in the Nordic region, specializes in life sciences venture capital. With extensive experience and a strong network, they focus on investing in innovative medical solutions addressing critical unmet needs. Their team, renowned for managing over €4 billion in assets and achieving numerous successful exits, collaborates closely with universities and incubators to drive advancements in therapies, medical technology, and digital health.

Sound Bioventures is a Venture Capital firm that Invests in private clinical stage biotherapeutics companies in Europe and USA. The fund has a geographic footprint on both sides of the Atlantic and will support the clinical development of novel medicines for diseases of high unmet medical need.

With the KBC Focus Fund, they have the ambition to boost the sectors of nanotechnology, microelectronics, and IoT. They mainly focus on Belgium and surrounding countries where top expertise centers in these technological areas can be found. KBC is also invested in university spin-off funds such as Gemma Frisius Fund and Qbic, as well as in Imec.xpand. This allows them to have great insights into deal flow and potential new ventures.

Red-stars invests in and manages companies that provide essential products and services for digitalization. They focus on mission-critical offerings in the Life Sciences sector. Their expertise ensures these companies meet the highest industry standards.

Investment is about building the future that lies ahead. Their investment opportunities are focused on AI because it drives the future of how machines, data, and technologies are being programmed. By channeling their deep domain expertise into identifying investment opportunities, they back AI companies with high potential to impact conventional industries or society.

Bioqube Ventures is a specialist life sciences investment firm based in Europe with a global footprint. They source, finance, and develop innovative therapeutic assets and technologies. They leverage their venture creation experience to translate and de-risk scientific innovation, advancing their investment portfolio and maximizing value for investors.